Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Durvalumab + Monalizumab|
Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 105||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Monalizumab||NN-8765|IPH-2201|IPH 2201|IPH2201||Monalizumab (IPH2201) is a humanized monoclonal antibody against NKG2A that blocks NKG2A ligand binding, which in turn induces cell-mediated immune response against cancer cells (PMID: 30503213, PMID: 31623687, PMID: 31308062).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03833440||Phase II||Ceralasertib + Durvalumab Durvalumab + Oleclumab Docetaxel Durvalumab + Monalizumab||Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)||Recruiting||FRA||0|
|NCT05221840||Phase III||Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab||A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN||16|
|NCT03794544||Phase II||Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + Monalizumab||Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer||Completed||USA | ITA | FRA | ESP | CAN||2|
|NCT03088059||Phase II||Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil||Biomarker-based Study in R/M SCCHN (UPSTREAM)||Recruiting||ITA | FRA | ESP | BEL||1|
|NCT03822351||Phase II||Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab||Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)||Active, not recruiting||USA | ITA | FRA | ESP | CAN||4|
|NCT05061550||Phase II||Durvalumab + Monalizumab Durvalumab + Oleclumab||Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)||Recruiting||USA | ITA | FRA | ESP | CAN | BEL||6|